LY-2157299 clinical trials
Also written LY2157299 and Galunisertib.
How each study uses LY-2157299 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the LY-2157299 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
23 studies that test it; most in 2014 (4)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 4 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 7
Eli Lilly and Company (15) · The Netherlands Cancer Institute (2) · Providence Health & Services (1) · University of Oklahoma (1) · Vanderbilt-Ingram Cancer Center (1) · Abramson Cancer Center at Penn Medicine (1) · Gipfel Life Sciences GmbH (1) · Sun Yat-sen University (1)
Often tested with
Tested in the same studies.
Paclitaxel (2) · Capecitabine (1) · Lomustine (1) · Carboplatin (1) · Sorafenib (1) · Nerandomilast (1) · Palbociclib (1) · Immune checkpoint inhibitors (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test LY-2157299, phase 3 first.
- Jun 2027This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic SignalingPhase 2/3 · Gipfel Life Sciences GmbH
- Dec 2026Galunisertib Combined With Capecitabine in Advanced CRC With PMPhase 1/2 · The Netherlands Cancer Institute
- Dec 2026Umbrella Biomarker-Guided Therapy in NPCPhase 2 · Sun Yat-sen University
Studies
Open first, then newest update. How each study uses LY-2157299 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 23
- This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic SignalingNot yet recruitingPhase 2/3Gipfel Life Sciences GmbHNCT07321860Written as Galunisertib + Nerandomilast Combination
- Umbrella Biomarker-Guided Therapy in NPCNot yet recruitingPhase 2Sun Yat-sen UniversityNCT04605562Written as Galunisertib
- Galunisertib Combined With Capecitabine in Advanced CRC With PMActive, not recruitingPhase 1/2The Netherlands Cancer InstituteNCT05700656Written as Galunisertib plus capecitabine
- ExIST Study of LY2157299 (Galunisertib) in Rectal CancerActive, not recruitingPhase 2Providence Health & ServicesNCT02688712Written as LY2157299
- A Study in Recurrent Glioblastoma (GB)CompletedPhase 2Eli Lilly and CompanyNCT01582269Written as Galunisertib
- A Dose-Escalation Study in Participants With Recurrent Malignant GliomaCompletedPhase 1Eli Lilly and CompanyNCT01682187Written as LY2157299
- Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or OvaryCompletedPhase 1University of OklahomaNCT03206177Written as Galunisertib
- Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast CancerCompletedPhase 1Vanderbilt-Ingram Cancer CenterNCT02672475Written as Galunisertib
- Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)CompletedPhase 1Abramson Cancer Center at Penn MedicineNCT02906397Written as Galunisertib 150mg by mouth twice a day
- A Study of LY2157299 in Participants With Advanced Hepatocellular CarcinomaCompletedPhase 2Eli Lilly and CompanyNCT02178358Written as LY2157299
- A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular CarcinomaCompletedPhase 1/2Eli Lilly and CompanyNCT02423343Written as Galunisertib
- A Study of LY2157299 in Participants With Hepatocellular CarcinomaCompletedPhase 2Eli Lilly and CompanyNCT01246986Written as LY2157299
- A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)CompletedPhase 1Eli Lilly and CompanyNCT02240433Written as LY2157299
- A Study of Galunisertib in Participants With Myelodysplastic SyndromesCompletedPhase 2/3Eli Lilly and CompanyNCT02008318Written as Galunisertib
- A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic CancerCompletedPhase 1Eli Lilly and CompanyNCT02734160Written as Galunisertib
- Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal CancerWithdrawnPhase 1/2The Netherlands Cancer InstituteNCT03470350Written as Galunisertib
- A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic CancerCompletedPhase 1/2Eli Lilly and CompanyNCT01373164Written as Galunisertib
- A Study of Galunisertib on the Immune System in Participants With CancerCompletedPhase 1Eli Lilly and CompanyNCT02304419Written as Galunisertib
- Study of Galunisertib in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT02752919Written as Galunisertib
- A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the BodyCompletedPhase 1Eli Lilly and CompanyNCT02154646Written as LY2157299
See all 23 studies that test LY-2157299 →
Given beside what is tested · 2 — LY-2157299 is usual care or a partner of the new treatment
- Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate CancerActive, not recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT02452008Written as LY2157299
- A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant GliomaCompletedPhase 1/2Eli Lilly and CompanyNCT01220271Written as LY2157299